NRD
KDNY

Nebula Research & Development’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Nebula Research & Development’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,856
Closed -$321K – 477
2023
Q1 		$321K Buy
+13,856
New +$330K 0.57% 38

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nebula Research & Development's KDNY Position: Q2 2023 in Review

Nebula Research & Development sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 13,856 shares — an estimated $321K sold.

Nebula Research & Development first reported a position in KDNY in Q1 2023 and held it in 1 quarter. The position peaked at $321K in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Nebula Research & Development reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Nebula Research & Development sold 13,856 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $321K.
  • Nebula Research & Development first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Nebula Research & Development's Chinook Therapeutics, Inc. Common Stock position peaked at $321K in Q1 2023.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Nebula Research & Development's 13F filing for Q2 2023, filed 14 Aug 2023.